标题
Afatinib: First Global Approval
作者
关键词
Epidermal Growth Factor Receptor, Trastuzumab, Gefitinib, Erlotinib, Objective Response Rate
出版物
DRUGS
Volume 73, Issue 13, Pages 1503-1515
出版商
Springer Nature
发表日期
2013-08-27
DOI
10.1007/s40265-013-0111-6
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- A phase Ib, open-label study to assess the safety of continuous oral treatment with afatinib in combination with two chemotherapy regimens: cisplatin plus paclitaxel and cisplatin plus 5-fluorouracil, in patients with advanced solid tumors
- (2013) J. B. Vermorken et al. ANNALS OF ONCOLOGY
- First-Line Management of EGFR-Mutated Advanced Lung Adenocarcinoma: Recent Developments
- (2013) Bin-Chi Liao et al. DRUGS
- Phase I dose-escalation study of afatinib, an ErbB family blocker, plus docetaxel in patients with advanced cancer
- (2013) John Marshall et al. Future Oncology
- Symptom and Quality of Life Benefit of Afatinib in Advanced Non–Small-Cell Lung Cancer Patients Previously Treated with Erlotinib or Gefitinib: Results of a Randomized Phase IIb/III Trial (LUX-Lung 1)
- (2013) Vera Hirsh et al. Journal of Thoracic Oncology
- Clinical perspective of afatinib in non-small cell lung cancer
- (2013) Xiaofeng Chen et al. LUNG CANCER
- Afatinib Prolongs Survival Compared with Gefitinib in an Epidermal Growth Factor Receptor-Driven Lung Cancer Model
- (2013) T. Ninomiya et al. MOLECULAR CANCER THERAPEUTICS
- Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab
- (2012) Gang Chen et al. BMC Medicine
- A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer
- (2012) Martin Schuler et al. BREAST CANCER RESEARCH AND TREATMENT
- A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab
- (2012) Nancy U. Lin et al. BREAST CANCER RESEARCH AND TREATMENT
- A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors
- (2012) Michael S. Gordon et al. INVESTIGATIONAL NEW DRUGS
- Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumors
- (2012) A. H. Awada et al. INVESTIGATIONAL NEW DRUGS
- A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors
- (2012) John Marshall et al. INVESTIGATIONAL NEW DRUGS
- Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial
- (2012) Vincent A Miller et al. LANCET ONCOLOGY
- Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial
- (2012) James Chih-Hsin Yang et al. LANCET ONCOLOGY
- Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu
- (2012) J. De Grève et al. LUNG CANCER
- Afatinib pharmacokinetics and metabolism after oral administration to healthy male volunteers
- (2011) Peter Stopfer et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4)
- (2011) H. Murakami et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Role of Genotyping in Non-Small Cell Lung Cancer Treatment
- (2011) Laura Bonanno et al. DRUGS
- Management of Recurrent Head and Neck Cancer
- (2011) Bruce E. Brockstein DRUGS
- The LUX-Lung clinical trial program of afatinib for non-small-cell lung cancer
- (2011) Giulio Metro et al. Expert Review of Anticancer Therapy
- Afatinib (BIBW 2992) development in non-small-cell lung cancer
- (2011) Vera Hirsh Future Oncology
- Phase I Trial of the Irreversible EGFR and HER2 Kinase Inhibitor BIBW 2992 in Patients With Advanced Solid Tumors
- (2010) Timothy A. Yap et al. JOURNAL OF CLINICAL ONCOLOGY
- BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
- (2008) D Li et al. ONCOGENE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started